This Government Contract opportunity from Department Of Health And Human Services was posted on August 15, 2022. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Top

Centers for Research on Structural Biology of Infectious Diseases

Awarded

75N93021R00009Federal

Submission Closed08/15/2022, 12:00:00 AM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 541714

New

Grant

MPS Platform Development & EngineeringThis subcontract focuses on the development and engineering of Microphysiological Systems and Organ-on-a-Chip platforms to support prime contractors on NIH/NIAID infectious disease projects. The scope of work involves engineering microfluidic devices, optimizing tissue-chip interfaces, and utilizing biocompatible polymers and precision pumps to integrate human variability into hardware and biological interfaces. The ultimate goal is to deliver a validated and reproducible platform that aligns with NIH and FDA guidance regarding New Approach Methodologies. Managed under the National Institutes of Health within the Department of Health and Human Services, the project falls under NAICS code 541714. The solicitation was posted on October 20, 2026, with a response deadline set for January 29, 2027.

National Institutes Of Health

POSTED

DEADLINE

Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed)

Solicitation # RFA-AI-28-012

The National Institute of Allergy and Infectious Diseases (NIAID) has issued solicitation RFA-AI-28-012 to establish a consortium of Translational Centers Using Microphysiological Systems for Infectious Diseases (TCMID). The primary objective is to refine and validate human tissue models using Microphysiological Systems (MPS) to a level consistent with regulatory qualifications, thereby promoting their adoption by product developers and reducing reliance on laboratory animals. This initiative aligns with NIH and FDA guidance on New Approach Methodologies (NAMs) to accelerate the development of safer medical interventions by capturing human variability and patient-specific characteristics. The program is structured around an Administrative Core, a Qualification Core, and Scientific Cores, with a heavy emphasis on technical readiness, reproducibility, and regulatory acceptance. Key deliverables include the validation of assays for specific endpoints and the submission of regulatory packages. Applicants must be domestic entities, as foreign organizations and foreign subawards are strictly prohibited. Required personnel must possess deep expertise in infectious diseases, MPS platforms, bioinformatics, and FDA submission processes. Applications are due by January 29, 2027, and must be submitted via the NIH ASSIST system or approved institutional system-to-system solutions. Evaluation is based on an overall impact score considering the project's significance, the suitability of the investigators, and the quality of the institutional environment. Mandatory application components include a Data Management and Sharing Plan and a Benchmarks and Timeline PDF not exceeding six pages. Awardees must also adhere to strict cybersecurity incident reporting guidelines, notifying HHS within 48 hours of any discovery.

National Institutes Of Health

POSTED

DEADLINE

Immune Tolerance Network (UM1 Clinical Trial Required)

Solicitation # RFA-AI-28-005

The National Institutes of Health, under the Department of Health and Human Services, is seeking applications through solicitation RFA-AI-28-005 to continue the Immune Tolerance Network (ITN). This cooperative agreement aims to develop tolerogenic therapies for immune-mediated disorders, specifically focusing on autoimmune diseases, allergic diseases and asthma, and the immune-mediated consequences of transplantation. The network operates through four integrated functional areas: Leadership, Clinical Operations, Core Laboratory, and Bioinformatics. Its primary objectives include designing and conducting clinical trials, performing integrated mechanistic studies, and sharing research results. Eligible applicants include small businesses and other for-profit organizations, though non-domestic entities are ineligible. Applications are evaluated based on scientific and technical merit, with a primary focus on significance and the likelihood of exerting a sustained influence on the research field. Key requirements include maintaining active registrations in SAM.gov, eRA Commons, and Grants.gov, as well as adhering to strict cybersecurity incident reporting and human subject protection protocols. The project requires a minimum effort of 3.6 person months per year for the PD/PI and mandates participation in a kick-off meeting in Bethesda, Maryland, and bi-annual steering meetings. Applications must follow specific page limits for the research strategy subsections and include detailed plans for clinical trial implementation, data management, and biorepository services.

National Institutes Of Health

POSTED

DEADLINE

Pre-Clinical Models of Infectious Diseases

Solicitation # 75N93027R00003

The National Institute of Allergy and Infectious Diseases (NIAID) is issuing a ramp-on solicitation to award multiple IDIQ base contracts for the Preclinical Models of Infectious Diseases program. This initiative aims to expand the existing pool of contractors capable of developing and refining animal and animal replacement models to evaluate medical countermeasures, such as vaccines, therapeutics, and diagnostics. The program bridges the gap between in vitro testing and clinical evaluation, supporting regulatory submissions and the advancement of countermeasures against priority biodefense and emerging infectious agents. Successful offerors will be eligible to compete for task orders across four specific areas: Small Animal Models, Non-Human Primate Models, Animal Replacement and Non-traditional Animal Models, and the Generation and Distribution of Specialized Reagents. The scope of work emphasizes a wide array of pathogens, including pandemic-potential RNA viruses, antimicrobial-resistant infections, fungal diseases, and neglected tropical diseases. Proposals must be submitted electronically via the NIAID eCPS website, and applicants are required to have a valid NIH eRA Commons account for authentication and secure transmission.

National Institutes Of Health Niaid

POSTED

DEADLINE

Alternative Protein Technologies for Military Field Feeding

Solicitation # W911QY27ALTPROTEINS

POSTED

DEADLINE

USDA SBIR/STTR Topic 8.2 — Plant Production and Protection - Biology

Solicitation # USDA-NIFA-TOPIC-8.2

The USDA National Institute of Food and Agriculture is soliciting proposals under Topic 8.2 for Plant Production and Protection - Biology. This initiative focuses on advancing crop production and protection through the development of innovative plant breeding methods, diagnostic technologies for diseases, and the creation of new food and non-food crop plants. Research efforts are directed toward improving plant characteristics to mitigate biotic and abiotic stresses, developing new genotypes for commercial applications, and creating tools to support the health of natural and domesticated pollinators. This opportunity is a total small business set-aside under the SBIR/STTR mandate, restricting eligibility to companies with fewer than 500 employees. Managed by the United States Department of Agriculture, the program is led by Dr. Christopher Philips. Interested parties can find further details and application guidelines through the NIFA website.

National Institute of Food and Agriculture

POSTED

DEADLINE

Artificial Blood and Medical Consumable InnovationThe Artificial Blood and Medical Consumable Innovation subcontract supports the Defense Advanced Research Projects Agency within the Department of Defense. The scope of work involves providing innovative medical consumables and conducting biochemical research specifically focused on the development of artificial blood for prime contractors on DARPA Biological Technologies Office projects. The contractor is responsible for engineering scalable manufacturing processes for these consumables using sterile manufacturing facilities and bio-reactors. Key deliverables include the production of artificial blood prototypes and the implementation of scalable medical consumable solutions. This effort falls under NAICS code 541714, with a response deadline set for November 15, 2026.

Defense Advanced Research Projects Agcy

POSTED

DEADLINE

Pre-Award Synopsis Texas Shield

Solicitation # DARPA-SN-27-07

The Defense Advanced Research Projects Agency (DARPA), through its Biological Technologies Office (BTO), intends to enter into an agreement with The University of Texas System consortium of universities for the Texas Shield Program. This integrated research initiative, identified by solicitation number DARPA-SN-27-07 and NAICS code 541714, focuses on developing autonomous and semi-autonomous medical technologies and scalable solutions for critical medical consumables. The primary goal is to support lifesaving medical care in contested, austere, and resource-limited environments. Key technical areas of focus include autonomous medical and robotic surgical systems, casualty evacuation, artificial-blood and supply innovation, AI-enabled clinical decision support, and mass-casualty science and simulation. This notice is a pre-award synopsis and is not a request for proposals or a competitive solicitation. Interested entities are invited to submit information by November 15, 2026, to TexasShieldxBTO@darpa.mil detailing their technical expertise, integrated research infrastructure, clinical-validation capabilities, and multi-institutional coordination capacity. Additionally, respondents must describe their consortium organizational structure, commercialization capabilities, facility clearance levels, and their ability to handle Controlled Unclassified Information. The government will not reimburse any costs associated with the preparation or submission of information in response to this notice.

Defense Advanced Research Projects Agcy

POSTED

DEADLINE

Q--AMPLICON SEQUENCING SERVICES

Solicitation # 140G0226Q0047

Solicitation 140G0226Q0047 is a firm-fixed-price request for a Blanket Purchase Agreement (BPA) to provide next generation amplicon sequencing services for the USGS Upper Midwest Water Science Center’s Michigan Bacteriological Research Laboratory. The scope of work includes providing all equipment, labor, travel, and materials necessary to support research on bacterial pathogens, harmful algal blooms, microbial ecology, antibiotic resistance, and microbial source tracking. Key technical requirements include the use of Illumina MiSeq or AVITI sequencing technologies and the potential for library preparation for 16S V4 amplicon sequencing. The BPA has a total not-to-exceed value of 250,000 dollars with an estimated period of performance from September 17, 2026, to September 16, 2031. The award process prioritizes non-priced factors significantly over cost, focusing on the offeror's qualifications and technical performance. Evaluation criteria include a detailed listing of on-site equipment and calibration dates, personnel experience, internal quality assurance procedures, and a technical narrative not exceeding two pages. Performance will be executed in Lansing, Michigan, with delivery terms set as FOB Destination. Administrative requirements include electronic invoicing via the Internet Payment Platform and compliance with various federal regulations, including the Buy American Act and specific security prohibitions regarding telecommunications equipment. Proposals must be submitted to the USGS OAG Denver Acquisition Branch by September 11, 2026.

Ofc Of Acquisition Grants-Denver

POSTED

DEADLINE

RFI Lupus Research Program (LRP) Public

Solicitation # HT9427RFI2027LRP

The Defense Health Agency, through the Congressionally Directed Medical Research Programs, has issued a Request for Information regarding the Lupus Research Program for fiscal year 2027. This action is strictly for information and planning purposes to identify future research focus areas and funding opportunities; it is not a solicitation, and no contracts will be awarded based on this announcement. The program aims to cure lupus by funding research to improve diagnosis, prevention, and treatment, with a specific focus on understanding biological or genetic patient subsets, disease mechanisms, and enhancing overall patient quality of life. Interested parties from academia, industry, non-profit organizations, and the public are invited to provide feedback on critical research gaps and underfunded areas. Responses must be submitted via Survey Monkey by November 16, 2026. While historical appropriations from fiscal years 2017 through 2024 and 2026 totaled 75 million dollars, funds for fiscal year 2027 have not yet been appropriated. Respondents are cautioned not to submit proprietary or sensitive information through the survey portal, as the government cannot protect such data, and all costs associated with responding to this request are the responsibility of the participant.

Defense Health Agency

POSTED

DEADLINE

Clinical Trial Site Operations and Participant ManagementThis subcontract for Clinical Trial Site Operations and Participant Management supports prime contractors on NIH/NIDDK projects through the direct execution of clinical trials. The scope of work includes recruiting and enrolling study participants, implementing lifestyle intervention weight loss programs, and conducting scheduled study visits and clinical procedures. To ensure compliance and quality, the provider must maintain IRB approval, active SAM/eRA Commons registration, and utilize specialized clinical trial facilities equipped with medical-grade ultra-low temperature freezers for biospecimen storage. The primary deliverables for this engagement consist of completed participant visits, curated patient data, and the collection of biospecimens. This opportunity is associated with NAICS code 541714 and falls under the jurisdiction of the National Institutes of Health within the Department of Health and Human Services. The response deadline for this requirement is November 17, 2026.

National Institutes Of Health

POSTED

DEADLINE

replacement skidsteerutility vehicle and attachmentsThe US Geological Survey, under the Department of the Interior, is forecasting the acquisition of a replacement skidsteer utility vehicle and associated attachments. This procurement is intended to support the National Wildlife Health Center located in Madison, Wisconsin, specifically benefiting the Midcontinent Region and Ecosystems Mission Area. The project is categorized under NAICS code 541714 and is listed as a forecast with a posted date of October 14, 2026. Sean Jones serves as the primary point of contact and small business specialist for this requirement.

US Geological Survey

POSTED

7 days ago

DEADLINE

N/A

AI Contract Overview

The National Institute of Allergy and Infectious Diseases, an agency of the Department of Health and Human Services, awarded a cost-reimbursement contract under full and open competition for the Centers for Research on Structural Biology of Infectious Diseases. This contract, identified by solicitation number 75N93021R00009 and NAICS code 541714, provides scientific support services focused on the 3D structure determination of protein targets. A cost-reimbursement structure was utilized because costs could not be adequately defined at the time of the award. The procurement process included a Request for Proposal issued in June 2021 and four subsequent amendments that clarified critical operational and financial guidelines. These amendments addressed protein target selection, equipment budgeting, subcontractor labor allocation, data privacy, and the eligibility of foreign researchers. Evaluation for the award was based on technical merit, cost, and past performance, with an emphasis on establishing new centers that complement existing research and collaborate on various pathogens.

General Info

Agency

Department Of Health And Human Services → National Institutes Of Health Niaid

Contract Value

$26,433,026

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Place of Performance

MD, USA

Set-Aside

NONE

Awardee

SEATTLE CHILDREN'S HOSPITAL

Award Issued Date

09/01/2022, 12:00:00 AM UTC

Documents

Amendment Four to Solicitation 75N93021R00009 for Structural Biology Research Centers

amendment

High

Amendment One to Solicitation 75N93021R00009 for Structural Biology Research

amendment

High

Amendment Three to Solicitation 75N93021R00009

amendment

High

Amendment Two to Solicitation 75N93021R00009

amendment

High

RFP 75N93021R00009 Centers for Research on Structural Biology of Infectious Diseases

rfp

High

AI Contract Breakdown

Uniform Contract Format

Contract not broken down yet

CLEATUS splits the solicitation into Uniform Contract Format (UCF) sections: scope, pricing, deliverables, and evaluation criteria.

Timeline

5 updates

PhaseAwarded

PostedJun 1

Presolicitation

Type ChangedJun 17

Presolicitation → Solicitation

Notice updatedJun 17

Notice details unchanged. Attachments may have changed.

Notice updatedJul 12

The notice description changed.

Notice updatedJul 22

The notice description changed.

Notice updatedAug 12

The notice description changed.

Notice updatedSep 3

The notice description changed.

AwardedSep 1

Contract was awarded

Submission Closed

08/15/2022, 12:00:00 AM UTC

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

AgencyDepartment Of Health And Human Services → National Institutes Of Health Niaid

Contacts2 people available

OfficeBETHESDA, MD, 20892, USA

Organization / AgencyDepartment Of Health And Human Services → National Institutes Of Health Niaid

Office AddressBETHESDA, MD, 20892, USA

Contacts

Swee L. Teo

Brian Madgey

Full Description

This cost-reimbursement contract award was made under full and open competition. This type of contract was selected because costs cannot be adequately defined at the time of contract award.